Aliskiren

CHEMBL1639 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
551.8 g/mol
LogP
3.5
Phase
4

A direct renin inhibitor that works at the very beginning of the renin-angiotensin-aldosterone system to reduce blood pressure, blocking the enzyme renin from initiating the cascade that leads to blood vessel constriction and sodium retention. It lowers blood pressure effectively and has been studied for its kidney-protective effects in patients with diabetes and hypertension.

Peso molecular

551,8000 g/mol

LogP

3,50

TPSA

146,00 Ų

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC

InChI

InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1

Molecular Formula

C30H53N3O6

HBD / HBA

4 / 7

Enlaces Rotables

19

Átomos Pesados

39

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A direct renin inhibitor that works at the very beginning of the renin-angiotensin-aldosterone system to reduce blood pressure, blocking the enzyme renin from initiating the cascade that leads to blood vessel constriction and sodium retention. It lowers blood pressure effectively and has been studied for its kidney-protective effects in patients with diabetes and hypertension.

Yes, Aliskiren is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1639. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5493444. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.